Posts in tag
PMV
PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021
PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activity Robust in vivo tumor regression observed with once daily oral dosing Pharmacodynamic biomarkers of p53 activation developed for clinical trials PC14586 is being tested in a Phase 1/2 clinical trial in patients with advanced solid tumors that have a p53 Y220C mutation CRANBURY, N.J., …